REPURPOSING POTENTIAL OF POSACONAZOLE AND GRAZOPREVIR AS INHIBITORS OF SARS‑COV‑2 HELICASE

dc.contributor.authorAbidi, Syed Hani
dc.contributor.authorAlmansour, Nahlah Makki
dc.contributor.authorAmerzhanov, Daulet
dc.contributor.authorAllemailem, Khaled S.
dc.contributor.authorRafaqat, Wardah
dc.contributor.authorIbrahim, Mahmoud A.A.
dc.contributor.authorla Fleur, Philip
dc.contributor.authorLukac, Martin
dc.contributor.authorAli, Syed
dc.date.accessioned2021-08-04T06:06:41Z
dc.date.available2021-08-04T06:06:41Z
dc.date.issued2021-05-13
dc.description.abstractAs the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic engulfs millions worldwide, the quest for vaccines or drugs against the virus continues. The helicase protein of SARS-CoV-2 represents an attractive target for drug discovery since inhibition of helicase activity can suppress viral replication. Using in silico approaches, we have identified drugs that interact with SARS-CoV-2 helicase based on the presence of amino acid arrangements matching binding sites of drugs in previously annotated protein structures. The drugs exhibiting an RMSD of ≤ 3.0 Å were further analyzed using molecular docking, molecular dynamics (MD) simulation, and post-MD analyses. Using these approaches, we found 12 drugs that showed strong interactions with SARS-CoV-2 helicase amino acids. The analyses were performed using the recently available SARS-CoV-2 helicase structure (PDB ID: 5RL6). Based on the MM-GBSA approach, out of the 12 drugs, two drugs, namely posaconazole and grazoprevir, showed the most favorable binding energy, − 54.8 and − 49.1 kcal/mol, respectively. Furthermore, of the amino acids found conserved among all human coronaviruses, 10/11 and 10/12 were targeted by, respectively, grazoprevir and posaconazole. These residues are part of the crucial DEAD-like helicase C and DEXXQc_Upf1-like/ DEAD-like helicase domains. Strong interactions of posaconazole and grazoprevir with conserved amino acids indicate that the drugs can be potent against SARS-CoV-2. Since the amino acids are conserved among the human coronaviruses, the virus is unlikely to develop resistance mutations against these drugs. Since these drugs are already in use, they may be immediately repurposed for SARS-CoV-2 therapy.en_US
dc.identifier.citationAbidi, S. H., Almansour, N. M., Amerzhanov, D., Allemailem, K. S., Rafaqat, W., Ibrahim, M. A. A., la Fleur, P., Lukac, M., & Ali, S. (2021). Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-89724-0en_US
dc.identifier.issn2045-2322
dc.identifier.urihttps://doi.org/10.1038/s41598-021-89724-0
dc.identifier.urihttps://www.nature.com/articles/s41598-021-89724-0
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/5650
dc.language.isoenen_US
dc.publisherNature Researchen_US
dc.relation.ispartofseriesScientific Reports;volume 11, Article number: 10290 (2021)
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectamideen_US
dc.subjectType of access: Open Accessen_US
dc.subjectResearch Subject Categories::MEDICINEen_US
dc.subjectantivirus agenten_US
dc.subjectcarbamic acid derivativeen_US
dc.subjectcyclopropane derivativeen_US
dc.subjectCOVID-19en_US
dc.titleREPURPOSING POTENTIAL OF POSACONAZOLE AND GRAZOPREVIR AS INHIBITORS OF SARS‑COV‑2 HELICASEen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Article 37.pdf
Size:
2.82 MB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections